|
rdf:type |
|
|
dailymed-instance:dosage |
Patients with Homozygous Familial Hypercholesterolemia:<br/>Adolescents (10-17 years of age) with Heterozygous Familial Hypercholesterolemia: National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 89(3):495-501. 1992.<br/>Concomitant Lipid-Lowering Therapy:<br/>Patients taking Cyclosporine or Danazol:<br/>Patients taking Amiodarone or Verapamil:<br/>Patients with Renal Insufficiency:
|
|
rdfs:label |
Simvastatin (Tablet, Film Coated)
|
|
dailymed-instance:clinicalP... |
Pharmacokinetics:<br/>Clinical Studies in Adults:<br/>Modifications of Lipid Profiles:<br/>Clinical Studies in Adolescents:
|
|
dailymed-instance:activeIng... |
|
|
dailymed-instance:genericDr... |
|
|
dailymed-instance:activeMoi... |
|
|
dailymed-instance:inactiveI... |
|
|
dailymed-instance:possibleD... |
|
|
dailymed-instance:precautio... |
General:<br/>Information for Patients:<br/>Drug Interactions:<br/>Other drug interactions:<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility:<br/>Pregnancy:<br/>Nursing Mothers:<br/>Pediatric Use:<br/>Geriatric Use:
|
|
dailymed-instance:genericMe... |
Simvastatin
|
|
dailymed-instance:fullName |
Simvastatin (Tablet, Film Coated)
|
|
dailymed-instance:adverseRe... |
Clinical Adverse Experiences:<br/>In Adults:<br/>Scandinavian Simvastatin Survival Study:<br/>Clinical Adverse Experiences:<br/>Heart Protection Study:<br/>Clinical Adverse Experiences:<br/>Laboratory Tests:<br/>Concomitant Lipid-Lowering Therapy:<br/>Adolescent Patients (ages 10-17 years):
|
|
dailymed-instance:warning |
Myopathy/Rhabdomyolysis:<br/>Liver Dysfunction:
|
|
dailymed-instance:indicatio... |
Reductions in Risk of CHD Mortality and Cardiovascular Events:<br/>Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles:<br/>Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH): The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C<130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined.<br/>General Recommendations:
|
|
dailymed-instance:represent... |
|
|
dailymed-instance:routeOfAd... |
|
|
dailymed-instance:name |
Simvastatin
|
|
skos:exactMatch |
|
